---
title: "Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study  | NBTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285126081.md"
description: "Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study | NBTX Stock News"
datetime: "2026-05-04T13:30:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285126081.md)
  - [en](https://longbridge.com/en/news/285126081.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285126081.md)
---

# Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study  | NBTX Stock News

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study | NBTX Stock News

### Related Stocks

- [NBTX.US](https://longbridge.com/en/quote/NBTX.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer](https://longbridge.com/en/news/286776980.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)